OYSTER POINT PHARMA, INC. (OYST): Price and Financial Metrics


OYSTER POINT PHARMA, INC. (OYST): $11.20

0.01 (+0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OYST to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OYST POWR Grades

  • OYST scores best on the Value dimension, with a Value rank ahead of 45.74% of US stocks.
  • OYST's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • OYST's current lowest rank is in the Sentiment metric (where it is better than 12.5% of US stocks).

OYST Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OYST is -0.88 -- better than only 5.11% of US stocks.
  • OYST's price/sales ratio is 15.34; that's higher than the P/S ratio of 93.15% of US stocks.
  • With a year-over-year growth in debt of 122.46%, OYSTER POINT PHARMA INC's debt growth rate surpasses 89.77% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to OYSTER POINT PHARMA INC, a group of peers worth examining would be DERM, NEO, STIM, LPRO, and BLBX.
  • Visit OYST's SEC page to see the company's official filings. To visit the company's web site, go to www.oysterpointrx.com.

OYST Valuation Summary

  • OYST's price/sales ratio is 15.3; this is 218.75% higher than that of the median Healthcare stock.
  • OYST's price/earnings ratio has moved up 13.7 over the prior 37 months.

Below are key valuation metrics over time for OYST.

Stock Date P/S P/B P/E EV/EBIT
OYST 2022-11-25 15.3 -13.5 -1.7 -2
OYST 2022-11-23 15.3 -13.5 -1.7 -2
OYST 2022-11-22 15.3 -13.5 -1.7 -2
OYST 2022-11-21 15.3 -13.5 -1.7 -2
OYST 2022-11-18 15.3 -13.5 -1.7 -2
OYST 2022-11-17 15.5 -13.6 -1.7 -2

OYST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OYST has a Quality Grade of D, ranking ahead of 7.23% of graded US stocks.
  • OYST's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows OYST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 18.015
2021-03-31 0 NA 14.414
2020-12-31 0 NA 13.189
2020-09-30 0 NA 16.062
2020-06-30 0 NA 34.495

OYST Price Target

For more insight on analysts targets of OYST, see our OYST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.50 Average Broker Recommendation 1.5 (Moderate Buy)

OYST Stock Price Chart Interactive Chart >

Price chart for OYST

OYST Price/Volume Stats

Current price $11.20 52-week high $19.98
Prev. close $11.19 52-week low $3.46
Day low $11.15 Volume 64,300
Day high $11.24 Avg. volume 203,924
50-day MA $8.42 Dividend yield N/A
200-day MA $7.38 Market Cap 300.65M

OYSTER POINT PHARMA, INC. (OYST) Company Bio


Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.


OYST Latest News Stream


Event/Time News Detail
Loading, please wait...

OYST Latest Social Stream


Loading social stream, please wait...

View Full OYST Social Stream

Latest OYST News From Around the Web

Below are the latest news stories about OYSTER POINT PHARMA INC that investors may wish to consider to help them evaluate OYST as an investment opportunity.

7 Cheap Large-Cap Stocks to Buy Before They Surge Higher

Even as they've delivered a solid performance so far this year, these seven cheap large-cap stocks to buy are still worth a look.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | November 28, 2022

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3’22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covere

Yahoo | November 10, 2022

Oyster Point Pharma Skyrockets on Viatris Deal

Shares of commercial-stage biopharmaceutical company Oyster Point Pharma (NASDAQ:OYST) are skyrocketing today after it agreed to be acquired by Viatris (NASDAQ:VTRS) for $11 per share. The strategic mover will make Oyster the cornerstone of Viatris’ new ophthalmology push. Under the deal, Viatris will now put forth a tender offer for Oyster shares at $11 apiece along with a contingent value right (CVR) cash component of $2 per share. The CVR would hinge on the achievement of performance targets by Oyster for 2022.

Kailas Salunkhe on TipRanks | November 7, 2022

Viatris (VTRS) Stock Pops 17% on Acquisition News

One press release with numerous positive catalysts is prompting some VTRS stock traders to load up on the shares today.

David Moadel on InvestorPlace | November 7, 2022

Viatris shares jump 13% on acquisitions, divestiture plan

Viatris Inc.'s shares rose 13% after the pharmaceutical company announced it had made two acquisitions in a new therapy area and then outlined more details on its previously announced $9 billion divestiture plan. Viatris (Nasdaq: VTRS), which is celebrating its two-year anniversary this month after the merger of Mylan NV and the Upjohn unit of Pfizer, said it was acquiring Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences for between $700 million and $750 million to build a vision medication business. Executive Chairman Robert J. Coury also disclosed during the call with analysts more details about its divestitures, which will include its over-the-counter business and women's care portfolio.

Yahoo | November 7, 2022

Read More 'OYST' Stories Here

OYST Price Returns

1-mo 42.86%
3-mo 78.34%
6-mo 190.16%
1-year 7.38%
3-year -33.77%
5-year N/A
YTD -38.66%
2021 -2.98%
2020 -23.00%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8785 seconds.